Implementation and effect of exercise and respiratory training on 6-minute walking distance in patients with severe chronic pulmonary hypertension: a randomized controlled multicenter trial in European countries - effect of exercise and respiratory training in patients with severe PH

Vrije Universiteit Medisch Centrum0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•1. Female and male patients of any ethnic origin *18 years
•2. WHO functional class II-IV
•3. PH diagnosed by right heart catheter showing:
•Baseline mean pulmonary arterial pressure (mPAP) * 25 mmHg
•Baseline pulmonary vascular resistance (PVR) * 240 dyn x s x cm-5
•Baseline pulmonary capillary wedge pressure (PCWP) * 15 mmHg
•4. Patients receiving optimized conventional PH therapy including intensified treatment with diuretics and who have been stable for 2 months before entering the study.
•5. Except for diuretics, medical treatment should not be expected to change during the entire 15-week study period.
•6. Negative pregnancy test (*-HCG) at the start of the trial and appropriate contraception throughout the study for women with child-bearing potential.
•7. Able to understand and willing to sign the Informed Consent Form

•1. PH of any cause other than permitted in the entry criteria, e.g. concomitantly to portal hypertension, complex congenital heart disease, reversed shunt, HIV infection, suspected pulmonary veno-occlusive disease based on pulmonary edema during a previous vasoreactivity test or on abnormal findings compatible with this diagnosis (septal lines or pulmonary edema at high resolution computer tomography), congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension or unclear diagnosis
•2. Pregnancy
•3. Patients with signs of right heart decompensation
•4. Walking disability
•5. Acute infection
•6. Pyrexia
•7. Any change in disease-targeted therapy within the last 2 months
•8. Any subject who is scheduled to receive an investigational drug during the course of this study
•9. Severe lung disease: FEV1/FVC <0.5 and total lung capacity <70% of the normal value
•10. Active myocarditis, instable angina pectoris, exercise induced ventricular arrhythmias, decompensated heart failure, active liver disease, porphyria or elevations of serum transaminases >3 x ULN (upper limit of normal) or bilirubin >1.5 x ULN
•11. Hemoglobin concentration of less than 75% of the lower limit of normal
•12. Systolic blood pressure <85 mmHg
•13. History or suspicion of inability to cooperate adequately.

发起方